Online weight loss treatment in Vermont
Surfbound connects eligible adults in Vermont with licensed providers for online GLP-1 weight-loss treatment review. Semaglutide $169/mo and tirzepatide $219/mo. Prescriptions are not guaranteed and are issued only when medically appropriate.
Can I start online GLP-1 weight loss treatment in Vermont?
Yes. Eligible adults across Vermont can begin an online GLP-1 weight-loss evaluation with Surfbound without an in-person visit. A licensed provider credentialed in Vermont reviews your health intake and, if treatment is medically appropriate, your prescription may be sent to a licensed pharmacy and shipped discreetly to your Vermont address. Semaglutide is $169/mo and tirzepatide is $219/mo; a prescription is never guaranteed.
The Green Mountain State · Northeast region. A rural state with limited obesity-medicine options. Telehealth-first across rural Vermont.
Cities in Vermont
Coverage across Vermont
Surfbound lists 5 Vermont cities with a dedicated local page. Care is delivered online, so you can also start from anywhere else in the state.
Provider access & processPricing and insurance
Semaglutide is $169/mo and tirzepatide is $219/mo. Clear pricing shown before checkout. Surfbound does not accept insurance at this time.
Shipping to Vermont
We prioritize fast shipping after provider approval and pharmacy processing. Tracking is provided; timing varies by pharmacy, location, weekends and holidays.
What's included in every Vermont plan
One flat monthly price covers the licensed provider review, medication if prescribed, and discreet shipping. There is no separate membership fee.
Vermont coverage & access
Practical answers about where you can start, how shipping works, and how to compare complete costs in Vermont. The Vermont provider access & process page covers the clinical steps in detail.
Surfbound lists 5 Vermont cities with a dedicated local page. Because care is delivered online, you can start from anywhere in Vermont — the city list is a navigation aid, not a limit on where you can begin.
The Vermont telehealth page explains how the online provider review works, what to prepare before your review, and how prescriptions and provider switches are handled. This coverage page links to it so you have one process reference and one coverage reference.
No. Surfbound is an online service with no physical offices in Vermont. You complete a health intake online, and a licensed provider credentialed in Vermont reviews your information remotely.
Compounded semaglutide is $169/mo and compounded tirzepatide is $219/mo, with the provider review included and no separate membership fee. Pricing is shown before checkout. Compounded medications are not FDA-approved.
If a provider determines treatment is medically appropriate, a prescription may be sent to a licensed compounding pharmacy and medication ships discreetly. Shipping is included; timing depends on pharmacy processing, your location, weekends, and holidays, and tracking is provided.
No. A prescription is issued only when a licensed provider determines treatment is medically appropriate after reviewing your health intake.
Yes. Already taking a GLP-1? We can match your current dose when clinically appropriate. Sign up and use the doctor-notes field at the end of the form to list your current medication and dose, and whether you want to stay at that dose or discuss increasing it. Your clinician reviews the request and determines the prescription. No written quote is required to switch.
The GLP-1 total-cost calculator lets you compare equal monthly recurring cost — including membership, shipping, and dose surcharges for any plan — against Surfbound's flat published price, so you can compare complete costs rather than a headline rate.
Surfbound is an online service. We do not have physical offices in Vermont. Licensed providers review health information online. A prescription is not guaranteed. Compounded medications are not FDA-approved.
Medical sources & references
Surfbound providers are licensed to practice in Vermont and follow applicable state medical board rules for telehealth. The following authoritative sources inform our treatment information.
- FDA — Human Drug CompoundingFDA guidance clarifying that compounded medications are not FDA-approved.
- FDA — Compounding: Questions and AnswersConfirms compounded drugs are not reviewed by FDA for safety or effectiveness.
- NIDDK (NIH) — Prescription Medications to Treat Overweight & ObesityNIH guidance on GLP-1 receptor agonists for medical weight management.
- CDC — Adult Obesity FactsNational adult obesity prevalence data referenced for regional context.
- ASMBS — American Society for Metabolic and Bariatric SurgeryProfessional guidance on metabolic and bariatric medicine.
- MedlinePlus (NIH) — Weight ControlConsumer health information on weight management from the National Library of Medicine.
Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. A prescription is not guaranteed and is issued only when a licensed provider determines treatment is medically appropriate.